Bionano Genomics, Inc. stock is up 11.28% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 2 CALLs, 2 PUTs. 0% of analysts rate it a buy.
Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
---|---|---|---|---|---|
11 Oct 16:53 | 17 May, 2024 | 4.00 | 22 | ||
13 Oct 13:57 | 16 Feb, 2024 | 6.00 | 150 | ||
13 Oct 19:04 | 17 May, 2024 | 3.00 | 1512 | ||
30 Oct 18:01 | 16 Feb, 2024 | 2.00 | 608 |
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping. NxClinical offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.